Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer
To identify germline polymorphisms to predict concurrent chemoradiation therapy (CCRT) response in esophageal cancer patients. A total of 139 esophageal cancer patients treated with CCRT (cisplatin-based chemotherapy combined with 40 Gy of irradiation) and subsequent esophagectomy were recruited at...
Saved in:
| Published in: | International journal of radiation oncology, biology, physics Vol. 82; no. 5; p. 1996 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.04.2012
|
| Subjects: | |
| ISSN: | 1879-355X, 1879-355X |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | To identify germline polymorphisms to predict concurrent chemoradiation therapy (CCRT) response in esophageal cancer patients.
A total of 139 esophageal cancer patients treated with CCRT (cisplatin-based chemotherapy combined with 40 Gy of irradiation) and subsequent esophagectomy were recruited at the National Taiwan University Hospital between 1997 and 2008. After excluding confounding factors (i.e., females and patients aged ≥70 years), 116 patients were enrolled to identify single nucleotide polymorphisms (SNPs) associated with specific CCRT responses. Genotyping arrays and mass spectrometry were used sequentially to determine germline polymorphisms from blood samples. These polymorphisms remain stable throughout disease progression, unlike somatic mutations from tumor tissues. Two-stage design and additive genetic models were adopted in this study.
From the 26 SNPs identified in the first stage, 2 SNPs were found to be significantly associated with CCRT response in the second stage. Single nucleotide polymorphism rs16863886, located between SGPP2 and FARSB on chromosome 2q36.1, was significantly associated with a 3.93-fold increase in pathologic complete response to CCRT (95% confidence interval 1.62-10.30) under additive models. Single nucleotide polymorphism rs4954256, located in ZRANB3 on chromosome 2q21.3, was associated with a 3.93-fold increase in pathologic complete response to CCRT (95% confidence interval 1.57-10.87). The predictive accuracy for CCRT response was 71.59% with these two SNPs combined.
This is the first study to identify germline polymorphisms with a high accuracy for predicting CCRT response in the treatment of esophageal cancer. |
|---|---|
| AbstractList | To identify germline polymorphisms to predict concurrent chemoradiation therapy (CCRT) response in esophageal cancer patients.
A total of 139 esophageal cancer patients treated with CCRT (cisplatin-based chemotherapy combined with 40 Gy of irradiation) and subsequent esophagectomy were recruited at the National Taiwan University Hospital between 1997 and 2008. After excluding confounding factors (i.e., females and patients aged ≥70 years), 116 patients were enrolled to identify single nucleotide polymorphisms (SNPs) associated with specific CCRT responses. Genotyping arrays and mass spectrometry were used sequentially to determine germline polymorphisms from blood samples. These polymorphisms remain stable throughout disease progression, unlike somatic mutations from tumor tissues. Two-stage design and additive genetic models were adopted in this study.
From the 26 SNPs identified in the first stage, 2 SNPs were found to be significantly associated with CCRT response in the second stage. Single nucleotide polymorphism rs16863886, located between SGPP2 and FARSB on chromosome 2q36.1, was significantly associated with a 3.93-fold increase in pathologic complete response to CCRT (95% confidence interval 1.62-10.30) under additive models. Single nucleotide polymorphism rs4954256, located in ZRANB3 on chromosome 2q21.3, was associated with a 3.93-fold increase in pathologic complete response to CCRT (95% confidence interval 1.57-10.87). The predictive accuracy for CCRT response was 71.59% with these two SNPs combined.
This is the first study to identify germline polymorphisms with a high accuracy for predicting CCRT response in the treatment of esophageal cancer. To identify germline polymorphisms to predict concurrent chemoradiation therapy (CCRT) response in esophageal cancer patients.PURPOSETo identify germline polymorphisms to predict concurrent chemoradiation therapy (CCRT) response in esophageal cancer patients.A total of 139 esophageal cancer patients treated with CCRT (cisplatin-based chemotherapy combined with 40 Gy of irradiation) and subsequent esophagectomy were recruited at the National Taiwan University Hospital between 1997 and 2008. After excluding confounding factors (i.e., females and patients aged ≥70 years), 116 patients were enrolled to identify single nucleotide polymorphisms (SNPs) associated with specific CCRT responses. Genotyping arrays and mass spectrometry were used sequentially to determine germline polymorphisms from blood samples. These polymorphisms remain stable throughout disease progression, unlike somatic mutations from tumor tissues. Two-stage design and additive genetic models were adopted in this study.MATERIALS AND METHODSA total of 139 esophageal cancer patients treated with CCRT (cisplatin-based chemotherapy combined with 40 Gy of irradiation) and subsequent esophagectomy were recruited at the National Taiwan University Hospital between 1997 and 2008. After excluding confounding factors (i.e., females and patients aged ≥70 years), 116 patients were enrolled to identify single nucleotide polymorphisms (SNPs) associated with specific CCRT responses. Genotyping arrays and mass spectrometry were used sequentially to determine germline polymorphisms from blood samples. These polymorphisms remain stable throughout disease progression, unlike somatic mutations from tumor tissues. Two-stage design and additive genetic models were adopted in this study.From the 26 SNPs identified in the first stage, 2 SNPs were found to be significantly associated with CCRT response in the second stage. Single nucleotide polymorphism rs16863886, located between SGPP2 and FARSB on chromosome 2q36.1, was significantly associated with a 3.93-fold increase in pathologic complete response to CCRT (95% confidence interval 1.62-10.30) under additive models. Single nucleotide polymorphism rs4954256, located in ZRANB3 on chromosome 2q21.3, was associated with a 3.93-fold increase in pathologic complete response to CCRT (95% confidence interval 1.57-10.87). The predictive accuracy for CCRT response was 71.59% with these two SNPs combined.RESULTSFrom the 26 SNPs identified in the first stage, 2 SNPs were found to be significantly associated with CCRT response in the second stage. Single nucleotide polymorphism rs16863886, located between SGPP2 and FARSB on chromosome 2q36.1, was significantly associated with a 3.93-fold increase in pathologic complete response to CCRT (95% confidence interval 1.62-10.30) under additive models. Single nucleotide polymorphism rs4954256, located in ZRANB3 on chromosome 2q21.3, was associated with a 3.93-fold increase in pathologic complete response to CCRT (95% confidence interval 1.57-10.87). The predictive accuracy for CCRT response was 71.59% with these two SNPs combined.This is the first study to identify germline polymorphisms with a high accuracy for predicting CCRT response in the treatment of esophageal cancer.CONCLUSIONSThis is the first study to identify germline polymorphisms with a high accuracy for predicting CCRT response in the treatment of esophageal cancer. |
| Author | Chen, Pei-Chun Hsiao, Chuhsing K Yang, Pei-Wen Lee, Yung-Chie Chen, Yen-Ching Lai, Liang-Chuan Lee, Jang-Ming Chuang, Eric Y Chen, Shin-Kuang Tsai, Mong-Hsun |
| Author_xml | – sequence: 1 givenname: Pei-Chun surname: Chen fullname: Chen, Pei-Chun organization: Department of Statistics and Informatics Science, Providence University, Taiwan – sequence: 2 givenname: Yen-Ching surname: Chen fullname: Chen, Yen-Ching – sequence: 3 givenname: Liang-Chuan surname: Lai fullname: Lai, Liang-Chuan – sequence: 4 givenname: Mong-Hsun surname: Tsai fullname: Tsai, Mong-Hsun – sequence: 5 givenname: Shin-Kuang surname: Chen fullname: Chen, Shin-Kuang – sequence: 6 givenname: Pei-Wen surname: Yang fullname: Yang, Pei-Wen – sequence: 7 givenname: Yung-Chie surname: Lee fullname: Lee, Yung-Chie – sequence: 8 givenname: Chuhsing K surname: Hsiao fullname: Hsiao, Chuhsing K – sequence: 9 givenname: Jang-Ming surname: Lee fullname: Lee, Jang-Ming – sequence: 10 givenname: Eric Y surname: Chuang fullname: Chuang, Eric Y |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21596488$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1KxDAYRYMozo--gUh2rlqTpu00Sxn8gwE3Drgr6Zev0wxtEpN2MW9vwRFc3bs49yzuilxaZ5GQO85Sznj5eEzNMbjGpxnjPGVZykR5QZa82shEFMXX5b--IKsYj4zN5Ca_JouMF7LMq2pJ2n1E6lp6wDD0xiL1rj8NLvjOxCFSY6kPqA2Mxh4oOAtTCGhHCh3OlNLGjR0G5U80YPTOzrZ5g9H5Th1Q9RSUBQw35KpVfcTbc67J_uX5c_uW7D5e37dPuwQKKcYk00znlS4kaGxELguNHEuoWtAyBy4gy3krykpxwUqBFVRMNTyHfFMgcAXZmjz8en1w3xPGsR5MBOx7ZdFNsZaZLNhGSDmT92dyagbUtQ9mUOFU_12T_QDFsmzq |
| CitedBy_id | crossref_primary_10_1016_j_suc_2012_07_013 crossref_primary_10_1111_nyas_12524 crossref_primary_10_1038_srep03850 crossref_primary_10_3892_ol_2016_5496 crossref_primary_10_1111_dote_12240 crossref_primary_10_1016_j_heliyon_2024_e33702 crossref_primary_10_2217_pgs_2016_0009 crossref_primary_10_1016_j_ejmp_2023_103182 crossref_primary_10_1016_j_pharmthera_2024_108591 crossref_primary_10_1038_srep10291 crossref_primary_10_1038_tpj_2015_46 crossref_primary_10_1093_carcin_bgy189 |
| ContentType | Journal Article |
| Copyright | Copyright © 2012 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2012 Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ijrobp.2011.02.036 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-355X |
| ExternalDocumentID | 21596488 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Taiwan |
| GeographicLocations_xml | – name: Taiwan |
| GroupedDBID | --- --K .1- .FO 0R~ 1B1 1P~ 1RT 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 AAEDT AAEDW AAQFI AAQQT AAWTL AAXUO ABJNI ABLJU ABNEU ABOCM ABUDA ACGFS ACIUM ACVFH ADBBV ADCNI ADVLN AENEX AEUPX AEVXI AFCTW AFPUW AFRHN AFTJW AGCQF AHHHB AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY CGR CUY CVF DU5 EBS ECM EFKBS EIF EJD F5P FDB GBLVA HED HMO HZ~ IHE J1W KOM LX3 M41 MO0 NPM O9- OC~ OO- RIG RNS ROL RPZ SDG SEL SES SSZ UV1 XH2 Z5R ~S- 7X8 |
| ID | FETCH-LOGICAL-c593t-2d0d48d59cdeb3495de1e6c8fcd94c13c241f368a13063e8c80ab14c475ec1ac2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 12 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000301891300078&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1879-355X |
| IngestDate | Thu Oct 02 06:47:38 EDT 2025 Mon Jul 21 05:58:07 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | Copyright © 2012 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c593t-2d0d48d59cdeb3495de1e6c8fcd94c13c241f368a13063e8c80ab14c475ec1ac2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 21596488 |
| PQID | 929507399 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_929507399 pubmed_primary_21596488 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-04-01 |
| PublicationDateYYYYMMDD | 2012-04-01 |
| PublicationDate_xml | – month: 04 year: 2012 text: 2012-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | International journal of radiation oncology, biology, physics |
| PublicationTitleAlternate | Int J Radiat Oncol Biol Phys |
| PublicationYear | 2012 |
| SSID | ssj0001174 |
| Score | 2.1046526 |
| Snippet | To identify germline polymorphisms to predict concurrent chemoradiation therapy (CCRT) response in esophageal cancer patients.
A total of 139 esophageal cancer... To identify germline polymorphisms to predict concurrent chemoradiation therapy (CCRT) response in esophageal cancer patients.PURPOSETo identify germline... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1996 |
| SubjectTerms | Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemoradiotherapy - methods Chromosomes, Human, Pair 2 - genetics Cisplatin - administration & dosage Disease Progression Esophageal Neoplasms - genetics Esophageal Neoplasms - therapy Esophagectomy Fluorouracil - administration & dosage Genome-Wide Association Study - methods Humans Linkage Disequilibrium - genetics Male Middle Aged Models, Genetic Polymorphism, Single Nucleotide Prospective Studies Radiotherapy Dosage Remission Induction - methods Taiwan Treatment Outcome |
| Title | Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21596488 https://www.proquest.com/docview/929507399 |
| Volume | 82 |
| WOSCitedRecordID | wos000301891300078&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8QwDI6AQ4iF9-N4KQNroE1fyYQQ4sTAnW4AqVvVOgkq4trSHkj373HaHkyIgaVTola2Y3-uv9iEXLoGcwwtDEPwKpmPkJlJoTMmPSFApQ6o7qLwYzSZiDiW056b0_S0yqVPbB21KsH-I7_GMB7YqpK8qd6ZHRpli6v9BI1VMvAQyVhGVxT_NAt3uybMdp42w7AaL2_OtfSu_LUus6rv4cmvHC_8HWO2sWa0_c-v3CFbPcikt51V7JIVXeyRjXFfRt8n5rnRtDT0Bd2yhZm0Kt8WsxJFnjezhuYFrWq72FKiKSbM0DVxoqhgXJWqvL-2taB1R7HVdo-2ExHQPeGbwdpSfUCeR_dPdw-sH7jAIJDenHHlKF-oQILCHBtTJ6VdHYIwoKQPrgcY7o0XihQDX-hpAcJJM9cHPwo0uCnwQ7JWlIU-JjSMQBmeclxvjSFDX8Yz4XMOKjRB5A0JXQowQYO2VYq00OVHk3yLcEiOOiUkVdd4I0F4IkP0OCd_bz4lm6ha3nFszsjA4GHW52QdPud5U1-0hoLPyXT8BfqYyxU |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+germline+polymorphisms+in+predicting+concurrent+chemoradiotherapy+response+in+esophageal+cancer&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Chen%2C+Pei-Chun&rft.au=Chen%2C+Yen-Ching&rft.au=Lai%2C+Liang-Chuan&rft.au=Tsai%2C+Mong-Hsun&rft.date=2012-04-01&rft.issn=1879-355X&rft.eissn=1879-355X&rft.volume=82&rft.issue=5&rft.spage=1996&rft_id=info:doi/10.1016%2Fj.ijrobp.2011.02.036&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1879-355X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1879-355X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1879-355X&client=summon |